“Biopreservation Market Report is set to have rapid growth due to consistent drug developments, advent of advanced therapies in the field of biomedical research and significant rise in patient base requiring high-end treatment for chronic diseases at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Biopreservation Market Forecast 2019-2029: By Product (Equipment, Media, LIMS), By Application (Regenerative Medicine, Bio-banking, Drug Discovery), By Cell Provider, Regional And Segment Forecasts

The global biopreservation market is poised for rapid growth between 2019 and 2029. The drivers include increasing healthcare expenditure, growing demand for preserving new-born’s stem cells, increasing R&D spending on research, and increasing adoption of regenerative medicine.

An increase in healthcare costs is also expected to improve access to quality health care and advanced products, which include biopreservation facilities, thus expanding growth prospects. In addition, hospitals, gene banks and biobanks, which are significant end users for this market, are encouraging key players to develop technologically advanced biopreservation products to improve patient outcomes.

The presence of government health initiatives that provide funds, grants and research contracts have led to an accelerated growth of research and development activities carried out by various companies. This, in turn, has led to the expansion of the possibility of adopting advanced bioconservation services, which is foreseen for the rate of fuel penetration during the forecast period.

Technological advances in biopreservation processes are also important growth factors that contribute to the market. Advances include the change in the formulation of hypothermic conservation solutions, next-generation cryopreservation solutions and design and integration with nanoscale technologies. These technological updates have led to the conservation and long-term storage of complex organs and tissues of great importance in regenerative medicine and organ transplantation.

Leading companies featured in the report include BioLife Solutions Inc., BioCision, Biomatrica, Chart MVE Biomedical, TissueGene, LabVantage Solutions, Panasonic Biomedical, Qiagen, Taylor-Wharton Cryogenics and Thermo Fisher Scientific

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever